載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.12
−US$0.03 · -2.61%
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
前收盤價
US$1.12
−US$0.03 · -2.61%
盤中時間採用ET。市場資料可能有所延遲。
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
日內區間
目前US$1.12
52週區間
目前US$1.12
盤中時間採用ET。市場資料可能有所延遲。
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
日內區間
目前US$1.12
52週區間
目前US$1.12
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 243.56萬 USD | 223.53萬 USD | 157.43萬 USD | 83.32萬 USD | 12.65萬 USD |
| 銷售、一般及管理費用 | 810.33萬 USD | 963.63萬 USD | 60.02萬 USD | 2.09萬 USD | 1.16萬 USD |
| 營業費用 | 1053.88萬 USD | 1224.22萬 USD | 394.2萬 USD | 85.41萬 USD | 13.81萬 USD |
| 利息收入 | 12.56萬 USD | 4.8萬 USD | — | — | — |
| 利息支出 | — | −433.85萬 USD | 164.3萬 USD | — | — |
| 折舊和攤銷 | — | 433.85萬 USD | — | 85.41萬 USD | 13.81萬 USD |
| 營業利益 | −1053.88萬 USD | −1224.22萬 USD | −394.2萬 USD | −85.41萬 USD | −13.81萬 USD |
| 淨利 | −1041.32萬 USD | −1653.27萬 USD | −1307.19萬 USD | −85.41萬 USD | −13.81萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
